BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30782614)

  • 1. Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition.
    Moison C; Lavallée VP; Thiollier C; Lehnertz B; Boivin I; Mayotte N; Gareau Y; Fréchette M; Blouin-Chagnon V; Corneau S; Lavallée S; Lemieux S; Marinier A; Hébert J; Sauvageau G
    Blood Adv; 2019 Feb; 3(4):552-563. PubMed ID: 30782614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
    Rudolph D; Impagnatiello MA; Blaukopf C; Sommer C; Gerlich DW; Roth M; Tontsch-Grunt U; Wernitznig A; Savarese F; Hofmann MH; Albrecht C; Geiselmann L; Reschke M; Garin-Chesa P; Zuber J; Moll J; Adolf GR; Kraut N
    J Pharmacol Exp Ther; 2015 Mar; 352(3):579-89. PubMed ID: 25576074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
    Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
    Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
    Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
    FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1).
    Wäsch R; Hasskarl J; Schnerch D; Lübbert M
    Recent Results Cancer Res; 2010; 184():215-8. PubMed ID: 20072841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
    Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A
    Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia.
    Oliveira JC; Pezuk JA; Brassesco MS; Morales AG; Queiroz RG; Scrideli CA; Tone LG
    Pediatr Blood Cancer; 2014 Jul; 61(7):1227-31. PubMed ID: 24519995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
    Müller-Tidow C; Bug G; Lübbert M; Krämer A; Krauter J; Valent P; Nachbaur D; Berdel WE; Ottmann OG; Fritsch H; Munzert G; Garin-Chesa P; Fleischer F; Taube T; Döhner H
    Br J Haematol; 2013 Oct; 163(2):214-22. PubMed ID: 24033250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.
    Tao YF; Li ZH; Du WW; Xu LX; Ren JL; Li XL; Fang F; Xie Y; Li M; Qian GH; Li YH; Li YP; Li G; Wu Y; Feng X; Wang J; He WQ; Hu SY; Lu J; Pan J
    Oncol Rep; 2017 Mar; 37(3):1419-1429. PubMed ID: 28184925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM4 overexpressed in acute myeloid leukemia patients with complex karyotype and wild-type TP53.
    Li L; Tan Y; Chen X; Xu Z; Yang S; Ren F; Guo H; Wang X; Chen Y; Li G; Wang H
    PLoS One; 2014; 9(11):e113088. PubMed ID: 25405759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells.
    de Oliveira JC; Brassesco MS; Pezuk JA; Morales AG; Valera ET; Montaldi AP; Sakamoto-Hojo ET; Scrideli CA; Tone LG
    J Drugs Dermatol; 2012 May; 11(5):587-92. PubMed ID: 22527426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Polo-like Kinase 1 as a Target for Anti-tumor Therapy].
    Procházková I; Vojtěšek B
    Klin Onkol; 2015; 28 Suppl 2():2S32-9. PubMed ID: 26374156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.
    Deng Z; Chen G; Liu S; Li Y; Zhong J; Zhang B; Li L; Huang H; Wang Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Nov; 206():112697. PubMed ID: 32814244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of TP53-Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity.
    Shin SB; Woo SU; Chin YW; Jang YJ; Yim H
    J Cell Physiol; 2017 Oct; 232(10):2818-2828. PubMed ID: 27861885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.